CAS: 78281-72-8; 2-(2-Amino-3-Benzoylphenyl)Acetamide

上下游产品

CAS号78281-61-5 2-氨基-3-苯甲酰基-alp... | CAS号2835-77-0 2-氨基二苯甲酮

专利信息

专利号:WO-2023075715-A1
优先权日:2021-10-26
标题 :A pharmaceutical formulation including leukotriene receptor antagonists and/or leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (nsaids)
发明人：OYTUN FARUK; CAN EFE
权利人:VSY BIYOTEKNOLOJI VE ILAC SANAYI ANONIM SIRKETI
摘要:This invention is related to a pharmaceutical formulation including Leukotriene receptor antagonists and/or Leukotriene synthesis inhibitors combined with non-steroidal anti-inflammatory drugs (NSAIDs) and antihistamines in ocular diseases and in inflammatory and allergic diseases for systemic and topical use. The objective of this invention is to create a novel formulation to be effective as much as steroids while having significantly less side effects for long-term use in treating ocular diseases, inflammatory and allergic diseases. In other words our aim is to achieve the inhibition of pro-inflammatory mediators (prostaglandins, thromboxane, histamine and leukotrienes) as much as steroids do with a safer combination.

专利号:US-6342524-B1
优先权日:1997-12-19
标 题:Use of non-steroidal anti-inflammatory agents in combination with compounds that have FP prostaglandin agonist activity to treat glaucoma and ocular hypertension
发明人：HELLBERG MARK R; NIXON JON C
权利人:ALCON MFG LTD
摘要:Disclosed are methods and compositions for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin analog and a prostaglandin synthesis inhibitor.

专利号:US-6646001-B2
优先权日:1997-12-19
标 题 :Use of non-steroidal anti-inflammatory agents in combination with prostaglandin FP receptor agonists to treat glaucoma and ocular hypertension
发明人：HELLBERG MARK R; NIXON JON C
权利人:ALCON MFG LTD
摘要:Disclosed are methods and compositions for the treatment of glaucoma and ocular hypertension, comprising the administration of a prostaglandin FP receptor agonist and a prostaglandin synthesis inhibitor.

专利号:WO-0195913-A1
优先权日:2000-06-13
标 题:Methods and compositions for the prevention of myopia
发明人：STJERNSCHANTZ JOHAN; RESUL BAHRAM
权利人:SYNPHORA AB; STJERNSCHANTZ JOHAN; RESUL BAHRAM
摘要:Exogenous prostaglandins and derivatives of prostaglandins as well as anti-inflammatory agents blocking prostaglandin synthesis are disclosed as useful for the prevention of the development of myopia. The prostaglandins should preferentially be administered topically on the eye, whereas the anti-inflammatory agents may be administered topically on the eye or orally. The administration may be continuous or intermittent.

专利号:US-2024058817-A1
优先权日:2021-01-27
标题 :Microfluidics Chips Useful in Nanoparticle Preparation and Expandable Pump Network System Useful Therewith
发明人：KOMPELLA UDAY; TAYLOR JONATHAN
权利人:UNIV COLORADO REGENTS
摘要:A system and method for nanoparticle synthesis employing an adhesiveless, deconstructable microfluidic mixing chip and an expandable wireless network of syringe pumps fluidly coupled to one or more microfluidic mixing chips. The wireless network of syringe pumps is controlled by a microprocessor with feedback from each of the syringe pumps in the network to allow for both individual, grouped and multiplexed control over the plurality of syringe pumps in the network.

专利号:US-10058505-B2
优先权日:2015-03-22
标题 :Transscleral drug delivery
发明人：MOUSAVIKHAMENE ZEYNAB; ABDEKHODAIE MOHAMMAD JAFAR; AHMADIEH HAMID
权利人:MOUSAVIKHAMENE ZEYNAB; ABDEKHODAIE MOHAMMAD JAFAR; AHMADIEH HAMID
摘要:Magnetic drug-loaded polymeric particles are used in a transscleral drug delivery method. In the synthesis process of the aforementioned magnetic drug-loaded polymeric particles, therapeutic agents, along with a magnetic agent are encapsulated in a polymer. The aforementioned magnetic drug-loaded particles can be placed near the outer surface of the sclera, and then a magnetic field can be applied in front of the eye to pull these magnetic drug-loaded particles to the outer surface of the sclera, where these particles adhere to the outer surface of the sclera and thus, the orbital clearance of the particles is eliminated or reduced.